Neuroscience 224, 282293
What the Research Actually Shows Published research on AOD-9604 describes: Modest body fat reduction in preclinical and early clinical settings Reduced triglycerides in some studies Minimal effect on IGF-1 confirmed across the clinical dataset Good tolerability adverse event rates in the phase 2 obesity trials were comparable to placebo Variable weight loss some patients respond better than others, consistent with many metabolic interventions The effect size in phase 2 obesity trials was modest typically in the range of a few pounds over the study period
poly) and fiber type (large, small, autonomic, mixed)
High affinity binding of LHRH in the anterior pituitary activates LH secretion by a calcium-dependent mechanism, resulting in LH secretion (Dufau and Catt, 2001)
The study evaluated daily supplementation over 28 days with defined endpoints including sleep quality and onset, calm response, mood, focus, energy, muscle relaxation, and tolerability
